Cargando…
A CRISPR/CAS9‐based strategy targets the personalized chimeric neosequence in fusion‐driven cancer genome for precision medicine
Autores principales: | Huang, Wei, Zeng, Zhan‐Cheng, Wang, Wen‐Tao, Sun, Yu‐Meng, Chen, Yue‐Qin, Luo, Xue‐Qun, Fang, Ke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967915/ https://www.ncbi.nlm.nih.gov/pubmed/33783997 http://dx.doi.org/10.1002/ctm2.355 |
Ejemplares similares
-
Enhanced genome editing efficiency of CRISPR PLUS: Cas9 chimeric fusion proteins
por: Park, Jongjin, et al.
Publicado: (2021) -
Author Correction: Enhanced genome editing efficiency of CRISPR PLUS: Cas9 chimeric fusion proteins
por: Park, Jongjin, et al.
Publicado: (2021) -
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
por: Ren, Jiangtao, et al.
Publicado: (2017) -
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
por: Xing, Hui, et al.
Publicado: (2019) -
Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling
por: Ravichandran, Mirunalini, et al.
Publicado: (2023)